BioNTech's Proposal to Acquire German mRNA Vaccine Competitor CureVac Will End on December 3
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Nov 26 2025
0mins
Source: SeekingAlpha
BioNTech's Acquisition of CureVac: BioNTech SE announced the approval of its exchange offer for all outstanding shares of CureVac N.V. at an extraordinary general meeting, with over 99.16% of CureVac shareholders voting in favor.
Transaction Details: The acquisition, valued at nearly $1.25 billion, is expected to be completed as soon as reasonably practicable, with the offer set to expire on December 3.
Shareholder Instructions: CureVac shareholders are advised to tender their shares by 6:00 pm Eastern Time on December 2 to meet operational deadlines.
Additional Context: The article also mentions BioNTech's ongoing strategies in oncology and its financial status, alongside Pfizer's plans to divest its remaining stake in BioNTech.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CVAC?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CVAC
About CVAC
CureVac CureVac NV, formerly CureVac AG, is a Germany-based clinical-stage biopharmaceutical company. The Company develops transformative medicines based on messenger ribonucleic acid, or mRNA. The Company's mRNAs are designed to prevent infections and to treat diseases by mimicking human biology to synthesize the desired proteins. Its technology platform optimizes mRNA constructs that encode functional proteins which either induce a desired immune response or replace defective or missing proteins using the cell’s intrinsic translation machinery. The Company's product portfolio includes clinical and preclinical candidates across multiple disease indications in prophylactic vaccines, oncology, and molecular therapy. In prophylactic vaccines, the Company is advancing its second-generation mRNA backbone against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and a range of infectious diseases, including seasonal influenza, in collaboration with GSK(Glaxo Smith Kline).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Honeywell Lowers FY2025 EPS Guidance to $9.70-$9.80 Amid Business Unit Discontinuation
- Guidance Reduction: Honeywell confirmed the discontinuation of its Advanced Materials business unit and lowered its FY2025 adjusted EPS guidance from $10.60-$10.70 to $9.70-$9.80, reflecting significant market challenges and pressure on profitability.
- Sales Forecast Cut: The company also reduced its sales guidance from $40.70 billion-$40.90 billion to $37.50 billion-$37.70 billion, indicating a cautious outlook on future market demand, which may impact investor confidence.
- Stock Price Reaction: In pre-market trading, Honeywell's shares fell 2.1% to $195.00, reflecting market concerns about the company's outlook and potentially increasing selling pressure among investors in the short term.
- Industry Impact: The discontinuation of this business unit and the guidance reduction may negatively affect Honeywell's market position in the materials sector, forcing the company to reassess its strategic direction to cope with intensifying competition.
Continue Reading
Clearwater Analytics (CWAN) Acquired by Private Equity Consortium for $8.4 Billion
- Acquisition Announcement: A consortium of private equity firms led by Permira and Warburg Pincus has announced a deal to acquire Clearwater Analytics for approximately $8.4 billion, including debt, indicating strong market interest in investment and accounting software companies.
- Stock Price Reaction: Clearwater Analytics shares surged 7.6% to $23.93 in pre-market trading, reflecting positive investor sentiment regarding the acquisition news, which may enhance the company's future market performance.
- Market Impact: This acquisition not only provides Clearwater Analytics with financial backing but also has the potential to accelerate its technological innovation and market expansion, strengthening its position in the highly competitive software industry.
- Industry Trend: With private equity firms continuing to invest in the software sector, more similar transactions are expected, further consolidating market resources and enhancing industry competitiveness.
Continue Reading